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PMD44
ADVANCING RISK ADJUSTMENT FOR
SCHIZOPHRENIA
Martin BC, Dorfman JH, Miller LS, Kotzan JA
University of Georgia, Athens, GA, USA
OBJECTIVE: The objective of this study was to develop
and validate a series of schizophrenia speciﬁc risk adjust-
ment cost models. METHODS: Georgia Medicaid claims
data linked with institutional inpatient data for 21,602
continuous eligible persons suffering from schizophrenia
was used to build a prospective diagnosis-based, a demo-
graphic-based, a drug-based, and a combined risk ad-
justment cost model. ICD-9-CM and drug category
classiﬁcations were derived from the literature and sup-
plemented by an expert panel. Variables were screened
and cost weights were derived empirically in a random
50% training sample using a robust a weighted Heuber-
White regression model and validated by expert panel
review, bootstrapping methods, and assessing indices of
discrimination in a 50% validation sample. Model cali-
bration and correlations of errors with policy relevant
groups were also estimated. RESULTS: Measures of dis-
crimination (R2) varied between 16.4% for the ICD-9-
CM based model to 21.8% for the combined model for
trimmed total cost and varied between 4.9% to 11.3%
for mental health costs in the validation sample. Risk
adjustment models based on drug or ICD-9-CM infor-
mation discriminated costs equally well and the combined
models outperformed both drug and ICD-9-CM based
models. A simple model using prior year costs combined
with demographic covariates had R2s > 40% for both
mental health and total costs. CONCLUSIONS: The drug
and ICD-9-CM based models performed equally well and
either can be used with equal conﬁdence depending on
data availability. The combined models performed better
than either the ICD-9-CM or drug based models indicat-
ing that drug exposure information can compliment more
traditional approaches. Health services researchers
wishing to control for differences in comorbidity and
severity that inﬂuence cost should always consider includ-
ing prior utilization (costs) since prior year costs were
vastly superior predictors of costs.
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OUTCOMES RESEARCH AND PHASE 1–2
PHARMACEUTICAL RISK ASSESSMENT
Lockett AE
Covance, Leeds, United Kingdom
OBJECTIVES: To determine the most effective way to
determine risk beneﬁt ratios in phase 1–2 developmental
compounds. The EMEA and FDA have recently published
discussion documents on the need to incorporate an
assessment of risk beneﬁt ratios during pharmaceutical
development. While methods are established for the
formal analysis of later stage development, the method to
assess risk in early development is unclear. This paper
seeks to identify what methods are available and assess
their application to risk-beneﬁt assessment in early stage
products. METHODS: A literature review of the methods
used to assess new technology risks. The nature of the
risks involved in early stage (phase 1 and 2) pharmaceu-
tical development were also identiﬁed from a database,
and the core values of the risks determined by established
frameworks. RESULTS: Four main methods were deter-
mined: formal analysis, bootstrapping, trade off and,
judgement analysis. In the analysis of the nature of the
risks of phase 1/2 pharmaceutical development much of
the risk can be described as voluntary risk, due to the
informed consent process. The acceptance of risk will
therefore vary with the severity of the condition and the
equity of the treatment being offered. The remainder of
the risk is outcome related, and so needs to be viewed in
the context of the aims of treatment. Comparing the
methods used to assess risk, only Judgement Analysis was
able to incorporate the degree of voluntary risk encoun-
tered in the risk assessment of pharmaceuticals in early
development. CONCLUSIONS: The ﬁnding that Judge-
ment Analysis is the only method to assess risk beneﬁt in
early stage development is controversial as it runs against
the statistical methods favoured by the regulators. The
results indicate a strong need to educate ethics commit-
tees and other clinical trial professionals in a wider range
of outcomes research.
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OBJECTIVES: Though economics is usually outcome-
oriented, it is often argued that processes matter as well.
Utility is not only derived from outcomes, but also from
the way this outcome is accomplished. Providing care on
a voluntary basis may especially be associated with such
process utility. In this paper we discuss the process utility
from providing informal care. We test the hypothesis that
informal caregivers derive utility not only from the
outcome of informal care, i.e. that the patient is ade-
quately cared for, but also from the process of providing
informal care. METHODS: We measure process utility as
the difference in utility between the current situation in
which the care recipient is cared for by the caregiver and
the hypothetical situation that someone else takes over
the care tasks, all other things equal. We present empiri-
cal evidence of process utility on the basis of a large
sample of Dutch caregivers (n = 950) and analyse these.
RESULTS: Our results show that process utility exists
